Daré Bioscience Statistics
Total Valuation
Daré Bioscience has a market cap or net worth of $26.75 million. The enterprise value is $24.75 million.
Important Dates
The next estimated earnings date is Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Daré Bioscience has 13.18 million shares outstanding. The number of shares has increased by 10.12% in one year.
| Current Share Class | 13.18M |
| Shares Outstanding | 13.18M |
| Shares Change (YoY) | +10.12% |
| Shares Change (QoQ) | +1.28% |
| Owned by Insiders (%) | 1.05% |
| Owned by Institutions (%) | 6.74% |
| Float | 11.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -1,511.46 |
| Forward PS | 2.91 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.34
| Current Ratio | 0.34 |
| Quick Ratio | 0.27 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -63.13% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 296.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$808,856 |
| Employee Count | 23 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.38% in the last 52 weeks. The beta is 1.14, so Daré Bioscience's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -44.38% |
| 50-Day Moving Average | 2.10 |
| 200-Day Moving Average | 2.67 |
| Relative Strength Index (RSI) | 43.25 |
| Average Volume (20 Days) | 201,561 |
Short Selling Information
The latest short interest is 185,018, so 1.40% of the outstanding shares have been sold short.
| Short Interest | 185,018 |
| Short Previous Month | 207,710 |
| Short % of Shares Out | 1.40% |
| Short % of Float | 1.59% |
| Short Ratio (days to cover) | 1.37 |
Income Statement
In the last 12 months, Daré Bioscience had revenue of -$17,701 and -$18.60 million in losses. Loss per share was -$2.14.
| Revenue | -17,701 |
| Gross Profit | -14.32M |
| Operating Income | -18.48M |
| Pretax Income | -18.60M |
| Net Income | -18.60M |
| EBITDA | -17.84M |
| EBIT | -18.48M |
| Loss Per Share | -$2.14 |
Full Income StatementBalance Sheet
The company has $5.04 million in cash and $3.03 million in debt, giving a net cash position of $2.00 million or $0.15 per share.
| Cash & Cash Equivalents | 5.04M |
| Total Debt | 3.03M |
| Net Cash | 2.00M |
| Net Cash Per Share | $0.15 |
| Equity (Book Value) | -12.73M |
| Book Value Per Share | -1.41 |
| Working Capital | -12.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.59 million and capital expenditures -$284,459, giving a free cash flow of -$11.87 million.
| Operating Cash Flow | -11.59M |
| Capital Expenditures | -284,459 |
| Free Cash Flow | -11.87M |
| FCF Per Share | -$0.90 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | 104,392.20% |
| Pretax Margin | 105,099.65% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Daré Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.12% |
| Shareholder Yield | -10.12% |
| Earnings Yield | -69.54% |
| FCF Yield | -44.37% |
Analyst Forecast
The average price target for Daré Bioscience is $10.00, which is 392.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 392.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 678.66% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2024. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jul 1, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
Daré Bioscience has an Altman Z-Score of -25.03 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -25.03 |
| Piotroski F-Score | 2 |
